Though harbored by only 4–6% of lung adenocarcinomas, EML4-ALK fusion has been recognized as the second most important event to consider in the targeted treatment of lung cancer, following the EGFR mutation [25, 26]. This evidence concerns the gene EGFR and lung cancer.